Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets open firm
Wed, 9 Jan 09:30 am

Barring Indonesia (down 0.1%) and South Korea (down 0.1%), the major Asian stock markets have opened the day on a positive note with stock markets in Hong Kong (up 0.4%) and Japan (up 0.4%) leading the gains. The Indian share market indices have opened the day in the on a firm note. All sectoral indices have opened in the green with stocks in the pharma and auto space leading the gains.

The Sensex today is up by around 45 points (0.2%), while the NSE-Nifty is up by around 13 points (0.2%). Mid and small cap stocks have opened in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.4% each. The rupee is trading at Rs 54.96 to the US dollar.

Auto stocks have opened the day mainly in green with Tata Motors Ltd and Ashok Leyland Ltd leading the gains. However, Bajaj Auto Ltd and Maharashtra Scooters Ltd witnessed selling pressure. As per a leading financial daily, Bajaj Auto Ltd has unveiled a new 100 cc motorcycle 'Discover 100T'. The motorcycle has been priced Rs 50,500 at ex-showroom New Delhi. The bike is powered by a patented four-valve DTS-i technology engine which delivers 10.2 ps of power. As per the management, the new bike is 30% more powerful than other motorcycles in this segment and delivers a fuel efficiency of 87 kilometers per litre. With this launch, the company is likely to strengthen its position in the country's entry-level bike market and gain market share from Hero MotoCorp Ltd. Currently, Bajaj Auto has a market share of 20% in the motorcycle segment. It expects that the new model will sell around 40,000-45,000 units a month and increase market share up to 32%. The entry-level segment in which the company has positioned its bike accounts for 65% of total motorcycle sales in India.

Indian Pharma stocks have opened the day mainly in green with Panacea Biotech Ltd and d Indoco Remedies Ltd leading the gains. As per a leading financial daily, Wockhardt Ltd has received final approval from the United States Food & Drug Administration (U.S. FDA) to market Lamotrigine, a drug used to treat epilepsy. As per the management, the company could market 25 milligrams (mg), 50 mg, 100 mg, 200 mg and 300 mg extended release tablets of Lamotrigine (the generic name for the brand Lamictal XR). The brand Lamictal XR is marketed in the U.S. by GlaxoSmithKline. The manufacturing of extended-release tablets of Lamotrigine will take place at the company's facility in Aurangabad with in-house technology. In U.S, the total market for this product is estimated at US$ 250 m.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.